0.0600USD-1.64%Mkt Cap: 1.75M USDP/E: 0.05Last update: 2026-06-01
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It develop…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.75M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.28M USD
Revenue/Share—
Last Price0.0600 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4268971045
Valuation
P/E (Trailing)0.05
P/E (Forward)-0.01
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.73
EPS (TTM)1.20
EPS (Forward)-11.43
52W Range
0.033012% of range0.2500
52W High0.2500 USD
52W Low0.0330 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-310.32%
ROA-269.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.27M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio—
Quick Ratio—
Book Value/Sh0.0840 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 3, 2019
Splits
Last Split1:50
Split DateMar 18, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.29.12M
Float—
Insiders25.76%
Institutions0.02%
Short Interest
Short Ratio0.1d
Short % Float4.10%
Short % Out.4.10%
Shares Short448.18K
Short (prev mo.)199.81K
Technical
SMA 500.0585 (+2.5%)
SMA 2000.0609 (-1.4%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)32.90K
Avg Vol (10d)38.94K
Technical Indicators
RSI (14)46.7
MACD0.0043
MACD Signal0.0071
MACD Hist.-0.0028
BB Upper0.1036 USD
BB Middle0.0722 USD
BB Lower0.0407 USD
BB Width87.10%
ATR (14)0.0148 USD
Vol Ratio (20d)0.34x